The renin-angiotensin-aldosterone system (RAAS) plays a vital role in regulating blood pressure, fluid volume, and sodium levels. An over-regulation of the system can result in life-threatening conditions. RAAS inhibitors are known to prevent proteinuria, kidney fibrosis, and slow the decline of renal function in patients with early and late stages of kidney disease. However, the plethora of associated adverse effects often makes them a difficult-to-choose option.
Additionally, the accurate management of resultant hypertension is crucial. Docplexus has organized an interactive webinar in association with the Care Institute of Medical Sciences and Joint International Conference 2020 , on 6 th July 2020, 7 pm onwards . In this webinar, experts will share their insights on the appropriate use of RAAS inhibitors in treating kidney disease and the changes in the guideline for the management…
